Michael Gibson
MD, PhD
Associate Professor of Medicine
Vanderbilt University Medical Center

Dr. Gibson is Associate Professor of Medicine at the Vanderbilt University, Vanderbilt-Ingram Cancer Center where he is Director of Translational Research for Head and Neck and Esophago-Gastric Oncology. His goal is to integrate the multidisciplinary pre-clinical research and clinical trials programs in head and neck and esophago-gastric cancers at the Vanderbilt-Ingram Cancer Center. He manages the trial portfolio for these diseases to integrate the research programs across disciplines and lines of care. He is Vice-Chair of the NCI Esophago-Gastric Task Force and a member of the NCCN Esophageal/Gastric Cancers Panel. He is study co-chair of EA2174 and EA 2183. He is co-leader along with Drs. Malcom Brock and Hajime Orita of the Juntendo/Johns Hopkins/Vanderbilt International Esophago-Gastric Collaboration. The overall goals of his research efforts are to bring novel therapeutics to the treatment of aero-digestive cancers based on rational pre-clinical investigation and in the setting of a focus on patient safety and outcomes.

Sessions

Register
General Session

Debate: Best Targeted Therapy for First-Line Gastroesophageal Cancer: PD-1 Inhibitors or Claudin-18.2 (CLDN18.2)? - CLDN18.2

Saturday, October 19, 2024
8:20 AM - 8:35 AM
General Session

Debate: Best Targeted Therapy for First-Line Gastroesophageal Cancer: PD-1 Inhibitors or Claudin-18.2 (CLDN18.2)? - DISCUSSION

Saturday, October 19, 2024
8:35 AM - 8:45 AM